Cetrorelix

Therapeutic

For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation

Structural features

SMILES

CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

Sequence

Ac-XXXSYXLRPa-NH2

Molar mass

1431.06 g/mol

Constitutional members:

10

Natural amino acids

5

D-Amino acids

5

N-terminus

acetyl

C-terminus

NH2

Cyclic

no

Members/cycle

N.A.

Bond to form cycle

N.A.

Lipidation

no

Glycosylation

no

Route of administration

SC

Terminal half-life

62.8 hours

Protein binding

0.86

Absorption and Bioavailability

0.85

References